I believe that most psychotherapy researchers, including readers of this In Review, have had the following experience. A friend or relative, whom you have not seen for a while, inquires about the status of your research. With minimal hesitation, you offer something in layman's terms such as: "I am trying to find out how effective different forms of psychotherapy are" [efficacy study] or "I am trying to find out which psychotherapy works best with which type of patient" [matching study] or "I am trying to find out which type of patients work well together in a psychotherapy group" [composition study]. Although rather straight-forward and seemingly clear, these examples are often met with a puzzled look that conveys the message "Are you still doing that?" or "Have you found anything new yet?" Just as there seems to be a wish among the general public to hear about new discoveries, there is a wish among psychotherapy researchers to be able to report new discoveries, not to mention breakthroughs. Unfortunately, in psychotherapy research, breakthroughs are few and far between, if they occur at all. For this reason, it was with definite interest and excitement on my part in anticipating the findings of the 2 papers in this In Review. 1, 2 They are devoted to "New Psychotherapies for Mood and Anxiety Disorders" 1 and to "Promising Psychotherapies for Personality Disorders" 2 (PDs). These disorders are very prevalent. Discoveries of effective new therapies for these disorders could be a considerable contribution to the field, particularly if they are shown to be more effective or less costly than previous therapies.
In the first review article, Dr Shannon Wiltsey Stirman, Ms Katherine Toder, and Dr Paul Crits-Christoph 1 identify so-called new therapies: 5 for mood disorders, 3 for posttraumatic stress disorder, and 2 for other anxiety disorders. These therapies were first introduced, or findings associated with them first reported, in the literature in the past 5 years (2004) (2005) (2006) (2007) (2008) (2009) ). The therapies carry such names as acceptance and commitment therapy, behavioural activation therapy, and positive psychotherapy. Evidence of efficacy, effectiveness, and specificity vary considerably among the therapies. While the authors attempt to maintain a sense of optimism about the benefits of future research with new therapies, a sense of disappointment permeates their conclusions. This is due largely to their conclusion that although substantial benefit is associated with the new therapies, none has been found to surpass the benefits of previous therapies. The authors present an engaging discussion that provides context for considering these new developments for the treatment of mood and anxiety disorders.
The second review article 2 had similar objectives, although with a markedly different sample of patients, those with PDs. In addition, the period of investigation was briefer (the past 3 years) and only randomized controlled trial (RCT) studies were included. Interestingly, the authors avoided calling treatments new, instead electing to call them promising. Perhaps they sensed how difficult it really is to clearly define new. Dr George Hadjipavlou and Dr John S Ogrodniczuk 2 reflect an increasingly positive pattern of response to treatment and prognosis. They identify numerous so-called psychotherapy packages that are backed up by evidence from the RCTs. Examples are mentalization-based therapy, transference-focused psychotherapy, and dialectical behavioural therapy. The authors provide an excellent discussion of the current state of psychotherapeutic treatment for PDs. They also correctly identified several limitations associated with studies in this area. Among these is the nearly exclusive focus on the treatment of borderline personality disorder (BPD), despite several recent commentaries in the literature that have appealed for more research on treatment of PDs other than BPD.
Other limitations that affect research on treatments of Axis I and II disorders include a short-sighted focus on pre-post therapy change to the exclusion of follow-up change. Recent research involving patients with complicated grief revealed distinct differences in patterns of pre-post and follow-up change with a substantial number of patients demonstrating delayed recovery; that is, nonsignificant change at posttherapy, but significant positive change at follow-up. 3 The positive outcomes of such patients would have been missed if follow-up change had not been monitored. Another limitation is that nearly all new treatments have been individual therapies, despite the promise that group therapy offers regarding cost-effective treatment.
The relative absence of group therapies in recent studies raises a question about the definition of new. Does the adaptation of a previous individual therapy into a group therapy format constitute the creation of a new therapy? Given that there are numerous therapeutic factors that are unique to group therapy, an argument can be made that the adaptation is indeed a new therapy. A similar question can be raised about the combination of any previously used therapies; that is, does the combination of 2 previous therapies constitute a new therapy?
Perhaps a more substantive question is: Why the emphasis on new therapies anyway? It is likely because grant agencies, scientific journals, and academic departments virtually demand that researchers engage in unique, novel, and cutting-edge research. This compels researchers to keep inventing (or reinventing) new treatments to seem like they are on to new breakthroughs. The consequence is that researchers receive little support and (or) credit for thoroughly and carefully studying old or established therapies to answer questions related to moderation, mediation, ease of dissemination, training feasibility, and cost-effectiveness. Thus it seems premature and perhaps inappropriate to move on to new therapies before we completely study and understand old ones.
Still, there is little doubt that, as long as our academic systems continue rewarding novel developments at the expense of careful scientific investigations, new therapies will continue to be developed at a fairly rapid pace. The reviews in this issue 1,2 provide an overview of some of the most contemporary developments in this regard. Nevertheless, whether viewed as truly new therapies or creative modifications of existing therapies is perhaps not that important. What is important is continuing to study psychotherapies, whether new or old, to the fullest extent to answer questions such as: Is this treatment effective in real-world settings? Are there particular types of patients for whom this treatment is especially effective? By which mechanisms does the treatment exert its effect? Does the treatment lead to increased savings for the health system in the long run? How easy is it to train therapists to provide this treatment competently? The authors of both reviews have given us many examples of new or quasi-new therapies that are worth exploring. Having steered us in the right directions, it is imperative to conduct the studies that will provide some answers to our questions. Usually that is when the fun of discovery begins.
What then should one say when questioned by an impatient friend or relative about "any breakthroughs yet?" Well, you can point out that good science cannot be rushed. Perhaps like fine wine, new is not always better.
